199 related articles for article (PubMed ID: 28917533)
21. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Zheng G; Zhao R; Xu A; Shen Z; Chen X; Shao J
Eur J Pharm Sci; 2018 Jan; 111():492-502. PubMed ID: 29107835
[TBL] [Abstract][Full Text] [Related]
22. Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
Li YJ; Dong M; Kong FM; Zhou JP
Int J Pharm; 2015 Jul; 489(1-2):83-90. PubMed ID: 25888801
[TBL] [Abstract][Full Text] [Related]
23. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
24. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
Liu Y; Feng L; Liu T; Zhang L; Yao Y; Yu D; Wang L; Zhang N
Nanoscale; 2014 Mar; 6(6):3231-42. PubMed ID: 24500240
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor.
Choi JW; Park JH; Cho HR; Chung JW; Kim DD; Kim HC; Cho HJ
Sci Rep; 2017 Apr; 7(1):554. PubMed ID: 28373713
[TBL] [Abstract][Full Text] [Related]
27. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
[TBL] [Abstract][Full Text] [Related]
28. Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors.
Chen J; Sheu AY; Li W; Zhang Z; Kim DH; Lewandowski RJ; Omary RA; Shea LD; Larson AC
J Control Release; 2014 Jun; 184():10-7. PubMed ID: 24727059
[TBL] [Abstract][Full Text] [Related]
29. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
Tsai JJ; Hsu FT; Pan PJ; Chen CW; Kuo YC
Anticancer Res; 2018 Apr; 38(4):2119-2125. PubMed ID: 29599330
[TBL] [Abstract][Full Text] [Related]
30. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma.
Yin X; Xiao Y; Han L; Zhang B; Wang T; Su Z; Zhang N
AAPS PharmSciTech; 2018 Jul; 19(5):2133-2143. PubMed ID: 29714002
[TBL] [Abstract][Full Text] [Related]
31. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells.
Kim DH; Jeong YI; Chung CW; Kim CH; Kwak TW; Lee HM; Kang DH
Int J Nanomedicine; 2013; 8():1697-711. PubMed ID: 23658488
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment.
Xiao Y; Liu Y; Yang S; Zhang B; Wang T; Jiang D; Zhang J; Yu D; Zhang N
Colloids Surf B Biointerfaces; 2016 May; 141():83-92. PubMed ID: 26844644
[TBL] [Abstract][Full Text] [Related]
35. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
Lin TsT; Gao DY; Liu YC; Sung YC; Wan D; Liu JY; Chiang T; Wang L; Chen Y
J Control Release; 2016 Jan; 221():62-70. PubMed ID: 26551344
[TBL] [Abstract][Full Text] [Related]
36. Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Kim GM; Kim MD; Kim do Y; Kim SH; Won JY; Park SI; Lee do Y; Shin W; Shin M
J Vasc Interv Radiol; 2016 Jul; 27(7):1086-92. PubMed ID: 27179404
[TBL] [Abstract][Full Text] [Related]
37. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
Maida M; Macaluso FS; Valenza F; Virdone R
J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
[TBL] [Abstract][Full Text] [Related]
38. Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
40. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]